{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:10:24Z","timestamp":1759569024509,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2595,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"crossref","award":["179571"],"award-info":[{"award-number":["179571"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"crossref","award":["3387671"],"award-info":[{"award-number":["3387671"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Oslo University Hospital, National Health and Medical Research Council","award":["1057762"],"award-info":[{"award-number":["1057762"]}]},{"name":"Medical and the Health Research Infrastructure Fund"},{"name":"L.T. Thean Memorial Scholarship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.exphem.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T12:16:07Z","timestamp":1422533767000},"page":"352-363.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The targeting of human and mouse B lymphocytes by dasatinib"],"prefix":"10.1016","volume":"43","author":[{"given":"Morten P.","family":"Oksvold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.","family":"Duyvestyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha A.","family":"Dagger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Forfang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June H.","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wallace Y.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2015.01.008_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib3","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"le Coutre","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","article-title":"Evolving treatment strategies for patients\u00a0newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy","volume":"26","author":"Shami","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2015.01.008_bib7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2015.01.008_bib11","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2012-09-457119","article-title":"Targeting the LYN\/HS1 signaling axis in chronic lymphocytic leukemia","volume":"121","author":"ten Hacken","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib12","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2015.01.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-2-4","article-title":"Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma","volume":"2","author":"Boukhiar","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.exphem.2015.01.008_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bjh.12573","article-title":"Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas","volume":"163","author":"Aalipour","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2015.01.008_bib15","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib16","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2015.01.008_bib17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2015.01.008_bib18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib19","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib20","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/10428190701671044","article-title":"Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825)","volume":"48","author":"Garc\u00eda-Mu\u00f1oz","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.01.008_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2015.01.008_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0022-1759(92)90228-L","article-title":"A new method for detachment of Dynabeads from positively selected B lymphocytes","volume":"146","author":"Rasmussen","year":"1992","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.exphem.2015.01.008_bib23","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.1002057107","article-title":"B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression","volume":"107","author":"Irish","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2015.01.008_bib24","doi-asserted-by":"crossref","first-page":"e94717","DOI":"10.1371\/journal.pone.0094717","article-title":"Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice","volume":"9","author":"Duyvestyn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2015.01.008_bib25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/leu.2008.163","article-title":"Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib","volume":"22","author":"Yang","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib26","first-page":"171","article-title":"Role of Bruton's tyrosine kinase in B cell development","volume":"8","author":"Maas","year":"2001","journal-title":"Dev Immunol"},{"key":"10.1016\/j.exphem.2015.01.008_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.184.1.31","article-title":"A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2","volume":"184","author":"Takata","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/emboj\/17.7.1973","article-title":"Btk\/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation","volume":"17","author":"Fluckiger","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2015.01.008_bib29","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2006-07-036418","article-title":"Combined deficiencies in Bruton tyrosine kinase and phospholipase C\u03b32 arrest B-cell development at a pre-BCR+ stage","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib30","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/11207580-000000000-00000","article-title":"Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"17","author":"McCormack","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.exphem.2015.01.008_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.exphem.2015.01.008_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature11885","article-title":"Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches","volume":"495","author":"Ding","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2015.01.008_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2015.01.008_bib34","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1038\/sj.onc.1208075","article-title":"Src-family kinases in B-cell development and signaling","volume":"23","author":"Gauld","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2015.01.008_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2656","article-title":"The follicular versus marginal zone B lymphocyte cell fate decision","volume":"9","author":"Pillai","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2015.01.008_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2015.01.008_bib37","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.4049\/jimmunol.1200649","article-title":"Lyn signaling to upregulate GANP is critical for the survival of high-affinity B cells in germinal centers of lymphoid organs","volume":"189","author":"Kuwahara","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2015.01.008_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice","volume":"3","author":"Nishizumi","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2015.01.008_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.21.120601.141107","article-title":"Positive and negative selection of T cells","volume":"21","author":"Starr","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.exphem.2015.01.008_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2141.2010.08507.x","article-title":"Dasatinib inhibits B cell receptor signalling in chronic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals","volume":"153","author":"McCaig","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2015.01.008_bib42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.exphem.2015.01.008_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","article-title":"BLNK: a central linker protein in B cell activation","volume":"9","author":"Fu","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2015.01.008_bib44","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V94.7.2357.419k40_2357_2364","article-title":"Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK\u2013functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling","volume":"94","author":"Hashimoto","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.01.008_bib45","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1073\/pnas.91.22.10606","article-title":"Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells","volume":"91","author":"Aoki","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2015.01.008_bib46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/cdd.2010.25","article-title":"Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia","volume":"17","author":"Harr","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2015.01.008_bib47","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a key target of imatinib and dasatinib in T-cell activation","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.01.008_bib48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ni893","article-title":"Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development","volume":"4","author":"Saijo","year":"2003","journal-title":"Nat Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X15000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X15000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:11Z","timestamp":1759566731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X15000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0301472X15000375"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2015.01.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The targeting of human and mouse B lymphocytes by dasatinib","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}